IL154370A0 - Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same - Google Patents

Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same

Info

Publication number
IL154370A0
IL154370A0 IL15437003A IL15437003A IL154370A0 IL 154370 A0 IL154370 A0 IL 154370A0 IL 15437003 A IL15437003 A IL 15437003A IL 15437003 A IL15437003 A IL 15437003A IL 154370 A0 IL154370 A0 IL 154370A0
Authority
IL
Israel
Prior art keywords
processes
preparation
same
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL15437003A
Other languages
English (en)
Original Assignee
Chemagis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemagis Ltd filed Critical Chemagis Ltd
Priority to IL15437003A priority Critical patent/IL154370A0/xx
Publication of IL154370A0 publication Critical patent/IL154370A0/xx
Priority to EP04737244A priority patent/EP1592399A1/en
Priority to PCT/IL2004/000031 priority patent/WO2004071486A1/en
Priority to US10/501,045 priority patent/US20050142190A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15437003A 2003-02-10 2003-02-10 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same IL154370A0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL15437003A IL154370A0 (en) 2003-02-10 2003-02-10 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
EP04737244A EP1592399A1 (en) 2003-02-10 2004-01-13 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
PCT/IL2004/000031 WO2004071486A1 (en) 2003-02-10 2004-01-13 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US10/501,045 US20050142190A1 (en) 2003-02-10 2004-01-13 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15437003A IL154370A0 (en) 2003-02-10 2003-02-10 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
IL154370A0 true IL154370A0 (en) 2003-09-17

Family

ID=30011990

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15437003A IL154370A0 (en) 2003-02-10 2003-02-10 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same

Country Status (4)

Country Link
US (1) US20050142190A1 (xx)
EP (1) EP1592399A1 (xx)
IL (1) IL154370A0 (xx)
WO (1) WO2004071486A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
AU2005288521A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
WO2006063025A1 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising donepezil
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2049510A1 (en) * 2006-07-28 2009-04-22 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of candesartan cilexetil form i
MY188367A (en) 2006-12-28 2021-12-06 Hoffmann La Roche Crystalline forms glyt1
DE102007037932A1 (de) 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
ES2324007A1 (es) * 2007-10-25 2009-07-28 Ferrer Internacional, S.A. Una forma amorfa de un compuesto antiinflamatorio.
WO2009055038A1 (en) * 2007-10-26 2009-04-30 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
BRPI1013901A2 (pt) * 2009-04-29 2019-09-24 Rexahn Pharmaceuticals Inc formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2016043975A1 (en) 2014-09-17 2016-03-24 Vm Pharma Llc Crystalline forms of tyrosine kinase inhibitors and their salts
US11104679B2 (en) * 2017-05-25 2021-08-31 Mingsight Pharmaceuticals, Inc. PKC inhibitor solid state forms
GB2581154B (en) * 2019-02-05 2022-09-28 Colvistec Ag Amorphous pharmaceutical compositions
JPWO2020261619A1 (xx) * 2019-06-26 2020-12-30

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
AU1153097A (en) * 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
HUP0501067A2 (en) * 2001-11-14 2006-02-28 Teva Pharma Amorphous and crystalline forms of losartan potassium and process for their preparation
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
AU2003278422A1 (en) * 2002-10-31 2004-05-25 Ranbaxy Laboratories Limited Amorphous form of losartan potassium

Also Published As

Publication number Publication date
EP1592399A1 (en) 2005-11-09
US20050142190A1 (en) 2005-06-30
WO2004071486B1 (en) 2004-11-18
WO2004071486A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
IL169500A0 (en) Pyrrolopyridazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL154370A0 (en) Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0401982A3 (en) Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
IL176005A0 (en) 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
IL170348A (en) Annals of Colest-4-and-3-On Oxes, Containing and Using Pharmaceutical Preparations
IL165388A0 (en) Macrolide compounds and pharmaceutical compositions containing the same
IL165012A0 (en) (S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
HU0301154D0 (en) Pharmaceutical composition
GB0300427D0 (en) Pharmaceutical composition
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
GB0307866D0 (en) Pharmaceutical composition
IL161428A0 (en) Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
GB0329232D0 (en) Pharmaceutical composition
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
GB0317663D0 (en) Pharmaceutical composition